Graves Disease
📧 Sign up to get email alerts when something new happens for Graves Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-10-13FDA Approved: PROPYLTHIOURACIL — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for Propylthiouracil from Actavis Pharma, Inc., under the ANDA pathway.
-
FDA approval · 2011-08-22FDA Approved: PROPYLTHIOURACIL — Supplemental Application (QUAGEN PHARMACEUTICALS LLC)
The FDA approved a supplemental ANDA for propylthiouracil from Quagen Pharmaceuticals LLC, authorizing the marketing of an additional generi…
-
FDA approval · 2011-08-22FDA Approved: METHIMAZOLE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for methimazole submitted by Chartwell RX, LLC. This action updates the product's labeling/manufactu…
-
CLINICAL_TRIALS trial_result · 2011-08-03Clinical Trial Update: Subtotal Versus Total Thyroidectomy for Graves' Disease [NA]
This clinical trial compares subtotal versus total thyroidectomy for Graves' disease. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2011-04-27Clinical Trial Update: Predictive Genetic Risk Assessment Trial
This Mayo Clinic-sponsored trial on Predictive Genetic Risk Assessment has completed, investigating genetic risk prediction across multiple …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2011-03-28FDA Approved: METHIMAZOLE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for methimazole submitted by Chartwell RX, LLC.
-
FDA approval · 2011-01-21FDA Approved: PROPYLTHIOURACIL — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for Propylthiouracil by Actavis Pharma, Inc., indicating a labeling update under the already app…
-
CLINICAL_TRIALS trial_result · 2010-12-28Clinical Trial Update: rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter [Phase 2]
A Phase 2 trial evaluated recombinant human thyroid-stimulating hormone (rhTSH) to influence thyroid size and optimize radioiodine therapy i…
-
CLINICAL_TRIALS research · 2010-12-22Clinical Trial Update: Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease
This document provides an update on a clinical trial investigating Digital Infrared Thermal Imaging (DITI) for Graves' disease. The current …
-
FDA approval · 2010-12-15FDA Approved: PROPYLTHIOURACIL — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for Propylthiouracil from Actavis Pharma, Inc., for the generic drug Propylthiouracil.
-
CLINICAL_TRIALS trial_result · 2008-10-20Clinical Trial Update: Effect of Lugol's Solution in the Patients With Graves' Disease
A completed clinical trial evaluated the effects of Lugol's Solution in patients with Graves' disease.
-
CLINICAL_TRIALS trial_result · 2008-05-22Clinical Trial Update: Treatment of M.Graves With Radioactive Iodine: Follow-up Study
Follow-up study evaluating radioactive iodine treatment for Graves' disease causing hyperthyroidism.
-
CLINICAL_TRIALS trial_result · 2008-05-14Clinical Trial Update: Low Doses of Cholestyramine in the Treatment of Hyperthyroidism [NA]
A completed clinical trial investigated low doses of cholestyramine for the treatment of Graves' disease-related hyperthyroidism.
-
CLINICAL_TRIALS trial_result · 2007-07-20Clinical Trial Update: Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves' Disease
The completed clinical trial investigated genetic polymorphisms associated with cigarette smoking and the risk of Graves' disease.
-
FDA approval · 2007-04-18FDA Approved: HICON — Supplemental Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)
The FDA approved a supplemental application for HICON (sodium iodide I-131) submitted by Jubilant DraxImage Inc., dba Jubilant Radiopharma.
-
CLINICAL_TRIALS trial_result · 2006-10-06Clinical Trial Update: Rituximab in the Treatment of Graves' Disease [Phase 1, Phase 2]
Clinical trial update reports on the use of Rituximab for Graves' disease and thyroid-associated ophthalmopathy in Phase 1/Phase 2 studies, …